Latest

Cannabis is all the rage these days. In fact, Grand View Research reports that the global legal marijuana market is expected to hit USD $146.4 billion by 2025, meaning your CannaBusiness is either at the forefront of this ever-changing industry, or will be left behind when those projected sales numbers hit.

To avoid getting smoked by the competition, let alone implode due to problems such as lack of traditional credit line access, cannabis start-ups must future-proof their position, evading the exigencies of this growing, yet capricious, market. 

One person who knows this well is Sara Branch. As the director of Technossus, a company renowned for accelerating businesses around tech, she helps advise organizations on how to implement emerging tools like AI.

Drawing on her extensive tech background, as well as experiences advising CannaBusinesses on their go-to market strategy, Branch offers three tips for brands looking to ride the wild weed wave to lasting profitability.

Automate Compliance

Automation is a big AI buzzword, but it also has implications for the cannabis space. Flying by the seat of your pants — or relying on a more analog, human-centric model for statute conformity — is dangerous, especially since rules change with locale. That’s why Branch has this simple advice for maximum adherence: “Don’t risk it. Take a page out of the AI playbook and mechanize processes to stay out of trouble.” 

Trying to be aware of, not to mention being compliant with, so many restrictions without the aid of automation isn’t just financially foolish, but it can lead to other deleterious consequences as well.

According to The Weed Initiate, incurred penalties can outstrip mere financial repercussions. “… You could also face full criminal liability, increased risk of federal prosecution, and expulsion from the cannabis industry.”

“When it comes to compliance software, this can be a make versus buy calculation, similar to a CRM,” says Branch. “Yes, off-the-shelf solutions work well for some companies. Meanwhile, other businesses invest in crafting their own CRM to fit their specific requirements. Neither is right or wrong so long as they serve the organization’s needs.” 

To Branch’s point, a host of software now exists to enable CannaBusinesses’ peace of mind when it comes to activities such as GPS tracking, RFID barcoding, inventory traceability and license management. Whatever form of automated compliance a business elects to use, it’s crucial to integrate it into both the technical and physical environment to garner the best ROI. 

Invest In A Data Infrastructure Around Cash

 Conventional banks don’t lend money to CannaBusiness due to federal restrictions. This poses uncommon problems, but, according to Michael Hawkins, CFO of the Medical Cannabis Innovations Group, “solutions and creative financing work-arounds do exist.”

This is where AI comes in handy, as the more a company can invest in its infrastructure, particularly understanding and tracking its cash on hand, the greater its ability to leverage such data in the future.

To understand how this works in practice, Branch suggests CannaBusinesses construct a roadmap around capital data sets.

“Spend time understanding this guide,” she says. “Not just year one, but years two to three. Make certain the technology you invest in will allow you to collect and mature your data landscape overtime.” 

Not only with this help from a consumer perspective, but also along all supply chain levels. Why? Collecting data about which suppliers are most reliable, as well as which one possess the best product and pricing, will produce patterns allowing for critical insights. Over time, these may lead to additional growth opportunities.

Still unconvinced that the money is in the data? Consider Headset. An analytics service provider, the company offers complex data so that businesses can better track their operations, including point of sale. This is especially helpful in the short-term by preventing out-of-stock debacles. Likewise, as the name suggests, Cannabis Big Data can also serve a useful analytic purpose. This company offers actionable insights stemming from public and proprietary sources to enhance revenue and lower costs.

Create Value Within A Supply Chain

Data analysis is something humans — and now AIs — can do to some extent. However, the real growth opportunity here exists for humans willing to do what they do best — and what AIs may never be to do at all; take action by integrating disparate information sources. Once a company can successfully understand its data, it is in its best interest to identify opportunities to be of help to others, especially along its supply chain.

To aid with this suggestion, senior management should ask itself, “Do we possess analytics we could share with the supply chain for greater insights?” The more (actionable) information a CannaBusiness can offer its supply chain, the more beneficial it will become to its partners, which can lead to greater efficiencies and revenue.

Ultimately, reciprocity goes a long way, especially in cannabis; a growth industry composed of interlocking relationships at every level. The more value a business can bring — not to just its immediate customers, but to its associates — the more poised for success it will be.

“Of all the tips this is the most important because it requires critical thinking,” says Branch. “Too often people misperceive A.I. as an intelligence agent divorced from human interaction. However, the savviest individuals and companies working in AI today realize its greatest benefit is its integration with human activities.”

The more CannaBusinesses begin to view tech as a reliable partner, the better positioned those businesses will be to take advantage of the high times now and in the future.

Read original article here.

Cannabis is now in 11 U.S. states, plus D.C., and that number continues to grow. Consumers 21 and older can now order cannabis products directly online and have them delivered right to their front door. It’s a dream come true for cannabis consumers, but there has been some controversy over age verification compliance during online transactions.

This new, highly controversial industry already endures scrutiny when cannabis and paraphernalia end up in the hands of underage consumers. As online sales increase, vendors must be able to confidently determine that an individual's digital identity matches the real-world person making the purchase (and that the customer is of legal age).

In fact, among persons aged 18 or older who reported lifetime marijuana use, almost 53 percent report first using marijuana between ages 12 and 17. About 2 percent report that they first used marijuana before age 12. Unfortunately, most identity and age verification methods fall short of that ask. 

Traditional Age Verification Methods Are Failing

Traditional methods of age verification depend on whether the product is being purchased online or within a dispensary. In online channels, companies rely solely on self-reporting, where the consumer simply interacts with a pop-up screen that asks for their date of birth. If the date of birth provided exceeds the minimum age requirement, the consumer can access the website and make online purchases. If the date doesn’t match, they’re denied access to the website.

On the other hand, the process for an in-store buyer is different and a bit more rigorous.

When a new user walks into a dispensary, they are often greeted by a “budtender” who will ask to see the customer’s driver’s license or other government-issued ID. They inspect the ID document, usually take a copy of it for their records, and sometimes ping a third-party database to verify the age and ensure the ID is legitimate. After the customer has been vetted and their age verified, they are usually asked to scan in their ID document on subsequent visits. The newly scanned ID is compared to the ID document on file to confirm it’s a match, and the user can then enter the dispensary and make cannabis purchases.

There are risks associated with either channel.

With the online channel, self-reported information provides virtually no actual proof of age and is unlikely to withstand any type of regulatory scrutiny. The in-store channel is a bit stronger because of the visual inspection of the ID document, but this avenue still lacks definitive proof because these documents can be so easily manipulated or even purchased off the dark web.

If someone provides an ID purporting to be John Smith at 123 Main Street and 21 years of age, how does the budtender know the ID is authentic? Unfortunately, there are so many security features embedded within today’s driver’s licenses, ID cards and passports, that it’s virtually impossible for untrained people to delineate between legitimate and fake IDs.

What Are The Implications Of Mismanaged Age Verification?

There are a number of potential repercussions of mismanaged age verification in the cannabis industry, all of which could hinder the growth of its legalization. Consider the current wave of legislation impacting the e-cigarette and vaping industry. As of September 2019, electronic cigarette users in New York are no longer able to buy such flavors as cotton candy under a new state ban approved by the Department of Health.

On a broader scale, Trump administration officials, alarmed by new data showing a huge jump in vaping by young people, are moving to ban most flavored e-cigarettes, a major development that could result in sweeping changes in the sprawling market. The cannabis industry should absolutely be shaking in its boots.

While many e-cigarette and vaping companies seemingly market their products to younger consumers, the cannabis industry is likely to be embroiled in a similar controversy. The repercussions for mismanaged age verification include hefty fines and brand damage (if local media get a hold of the story). If there’s enough bad press, then many jurisdictions may be forced to outlaw the sale of cannabis within their city or township.

What Can Be Done To Ensure Cannabis Consumers Are The Age They Claim To Be?

Thankfully, our ever-evolving technology market can offer an incredibly accurate and safe means of age verification to not only protect suppliers from scrutiny, but the industry altogether. For example, face-based biometric verification can offer a viable alternative to current methods of age verification.

When combined with advanced technologies, like artificial intelligence and certified liveness detection, these methods can provide powerful disincentive for underage customers using a parent’s ID or a fake ID. In order to assess the validity of the ID, these types of solutions can capture ID documents, extract the data to assess their authenticity, and then use computer vision, machine learning and AI together to verify IDs in real time.
This type of methodology provides a much more comprehensive means validating a consumer’s age and goes further than just your general check box or quick glance at a government-issued ID. This is just one example of a potential solution to a sweeping issue in the industry and a giant step up from the methods being used currently. Many highly-regulated industries — like banking and online gaming — are also resorting to face-based authentication to meet intense regulatory demands, so the cannabis industry is not alone in its struggles.

It’s clearly time to evolve beyond self-reported age verification. This is integral for online sales, but also vitally important at in-store dispensaries, as most budtenders are not fully equipped to identify fake IDs. Dispensaries need to pay attention to the current e-cigarette and vaping climate, and take every measure to stay above the fray, and this starts with reliable age verification. The good news is there are already proven methods, used by other industries, that can provide a much higher level of age verification assurance that can better withstand regulatory and jurisdictional scrutiny.

Medical marijuana firm AMP German Cannabis Group announced that it will begin auditing its supply chain in accordance with the European Union (EU) Good Manufacturing Procedure (EU-GMP) to "ensure the quality and integrity of pharmaceutical goods" as they move through the supply chain from the supplier to the German patient.

Legalization of medical marijuana in Germany happened fairly recently (in 2017), while recreational cannabis continues to remain illegal. Nonetheless, even with medical marijuana being legal, patients still face significant difficulties in procuring it as Germany contends with supply shortages and unnaturally high shelf prices.

This ultimately boils down to the confusing reality of laws that govern marijuana in Germany. Since marijuana is still classified under narcotics and carries a state prohibition on its growth, sale and distribution, domestic cannabis fields cannot exist in Germany – making patients rely entirely on pharmaceutical imports for their needs. 

Recognizing a huge opportunity, several foreign pharmaceutical companies have taken an interest in importing medical marijuana in Germany. A growing number of doctors jump onto the cannabis bandwagon every year, endorsing cannabis therapies for a variety of ailments, and thus creating a perfect recipe for the medical marijuana supply chain to flourish. 

For AMP, the EU-GMP certification will help push products earmarked to meet the highest consumer health and safety standards. Meeting these standards will also ensure a more effortless entry into the German market. 

"In addition to ensuring the suppliers' production and operating processes meet EU-GMP certification standards, AMP's German pharmaceutical consulting partner will audit AMP's supply chain service providers during the fourth quarter of 2019 to ensure the quality and integrity of the pharmaceutical goods is maintained during transportation, warehousing, handling, testing and distribution," said the company in a statement. 

The idea of EU-GMP certification apart, global cannabis supply chains can also look to leverage the technology of blockchain to bring transparency and visibility into the movement of marijuana from the field to the pharmacy counter. Blockchain can also ensure accountability from every stakeholder across the value chain, as the decentralized ledger technology demands equal participation and responsibility from every party involved. 

Pushing all the stakeholders onto a single decentralized blockchain network will also eliminate possibilities of counterfeit cannabis products making their way into the supply chain. Marijuana cultivation produces a lot of waste and some plants die along the way, which makes it vital to keep an accurate measure on the volume of harvested cannabis to ensure safety. 

AMP expects its first imports into Germany to begin by the first half of 2020. AMP will be procuring its medical cannabis from two licensed producers based in the state of Alberta, Canada. The supply agreements will be made more concrete once these producers clear the audit for EU-GMP certification and receive their sales license from Health Canada. 

AMP will check the medical cannabis products before they are transported from Canada to Frankfurt, Germany, via air freight. Upon landing in Frankfurt, the products will be stored at a narcotics storage facility. The products will be inspected one last time before they are cleared to be sold to German pharmaceutical wholesalers. These wholesalers will only be allowed to sell the stocks to pharmacists who are contractually bound to AMP for their medical cannabis supply – thus ensuring strict accountability over the cannabis inventory.

A row is brewing between the ACT and Federal Government over controversial moves to legalise cannabis in Canberra from early next year.

The ACT Government last month passed legislation legalising possessing, smoking and growing small amounts of cannabis from early next year.

Adults can possess up to 50 grams of dry cannabis and grow two plants.

The passage of the laws appeared to take many within the Federal Government by surprise, and prompted a strong response, with some senior Government ministers labelling it "crazy" and suggesting the ACT Government was spending "too much time smoking hooch".

Mr Hunt wrote to Mr Barr this week detailing his concerns around the potential health impacts of the legislation, and querying how his Government came to support the private members bill.

Follow this story to get email or text alerts from ABC News when there is a future article following this storyline.

"I have serious concerns the ACT's legislation will result in further health harms and exacerbate mental health issues, particularly for those who have a family history of mental health disorders," he wrote.

"I note that both the Australian Medical Association and the Royal Australian College of Surgeons have also expressed concerns over the legislation, with the latter calling for it to be reversed."

Mr Hunt attached a dossier of research and briefings on both the physical and mental health effects of recreational use of cannabis, to back up his claims.

"I call on you to explain whether the ACT Government considered the international evidence on the health effects of cannabis and to provide any evidence to the contrary," he wrote.

Within the letter, Mr Hunt noted the global direction on regulation of cannabis was towards legalisation and decriminalisation, but he suggested that was prompting more research into its adverse effects.

A spokeswoman for the ACT Government said they intended "to respond fulsomely to Mr Hunt's letter" in the coming days.

The health impacts of the legislation are not the only potential point of conflict between the Federal and ACT Governments over the contentious legislation.

Federal Attorney-General Christian Porter is still considering the legalities of the bill, although the final version of the legislation is yet to be published.

The ACT laws directly conflict with Commonwealth legislation, which prohibits the possession of cannabis.

Mr Porter has not ruled out seeking to have the laws overturned.

Standard units for grading the potency of cannabis – similar to those already used for alcohol – would result in significant improvements in the mental health of users, according to addiction experts.

Researchers from the Addiction and Mental Health Group at the University of Bath, working with staff from King’s College London, UCL and the Australian Catholic University in Melbourne, say more needs to be done to make people aware of the levels of THC – the main psychoactive component – in the cannabis they are consuming.

Writing in the journal Addiction, the experts suggest a unit level should be set at 5mg of THC – the amount that would typically be found in a small joint. This is enough to induce intoxication but without psychotic symptoms, they say.

“Our findings add to a growing body of evidence that suggests the health effects of cannabis are dose-related,” said lead author Sam Craft, from King’s College London. “We believe a unit system would help both users and healthcare professionals by providing clearer information on the types of cannabis products and their strength.”

Previous research from the team has highlighted how concentrations of THC in cannabis have doubled across Europe in the past decade. But although use of the drug is widespread and there are moves in some countries to legalise it, standard units – which have been commonplace for alcohol for many years – have not been adopted in health guidelines.

The authors believe that a standard unit system would also yield benefits for countries where cannabis use is illegal, such as the UK. “Where the unit system for alcohol has helped consumers to better manage their alcohol intake, so, too, this could have important implications for cannabis users,” said senior author Dr Tom Freeman from the University of Bath. “This should give clear guidance about the dose of THC people are consuming. Our hope is that the introduction of a system in locations where the drug is legalised will have knock-on effects to countries where it is not, providing users and clinicians with an important toolkit to guide safer use.”

The publication coincides with a second study from the team, published in the journal Psychological Medicine, which examines the relationship between cannabis and key health outcomes in more than 55,000 people across 175 countries.

Using the Global Drug Survey, consumers were asked about the types of cannabis they used and their health. The results showed those who used higher THC forms of cannabis, such as hashish, experienced more severe health problems than those using traditional herbal products with lower levels of THC.

A ruling by Finland’s Supreme Court means that motorists will likely not be charged for driving under the influence days after using cannabis.

The influence of cannabis on users dissipates after some hours, however its "fingerprints" remain in the body for even longer. The court ruling aims to recognise that compounds related to metabolising cannabis may remain in the body for days after using the drug, although the user's ability to drive may not be impaired.

In Finland using cannabis is still illegal and drivers are still likely to be charged for the offence if they get behind the wheel hours after indulging in its use.

Cannabis usage leaves a substance known as tetrahydrocannabinol or THC in the body, prompting the production of a metabolite, carboxytetrahydrocannabinol (THC-COOH, where a metabolite is a substance required for or produced from metabolism.

THC is a psychoactive substance, which intoxicates people, so detecting it in a driver’s bold always results in a charge for driving under the influence. In Finland, police generally also issue a DUI citation if they find the metabolite THC-COOH in the blood.

However there is a major difference between the compounds.

Depending on the dosage taken, THC is known to leave the body between six and eight hours after cannabis use. However metabolites like THC-COOH may show up in blood samples for days or weeks longer. It is the equivalent of a cannabis "fingerprint" that reveals use of the drug in the recent past.

Unlike THC, the metabolite THC-COOH does not have an intoxicating effect and therefore does not impair the ability to drive.

According to Teemu Gunnar, a forensic toxicologist with the National Institute of Health and Welfare, THL, it makes sense that identifying THC-COOH in the blood should not automatically lead to a DUI sanction.

"It’s quite rational that finding it several days after use would not lead to a drunk driving penalty because it does not affect the ability to drive," he said.

Supreme Court decision changes police and prosecutor practices

A few years ago the Supreme Court dismissed an appeal court conviction in the case of a driver who had smoked cannabis before getting behind the wheel. THC-COOH "does not affect the ability to drive nor endanger traffic safety even at high levels," the court said in its ruling.

Since that ruling, police and prosecutors have changed their practices to bring them in line with the court’s judgment. Prosecutors no longer press charges solely on the basis of the presence of THC-COOH in the blood, or when the police have confirmed that there is no reason to suspect an offence was committed.

"We have acted in accordance with the Supreme Court guideline, in other words for the most part we do not lay charges. Before [the precedent] it led to charges," noted district prosecutor Tero Kekki.

"We have reacted and practices have changed. So we don’t do any unnecessary work," commented detective inspector Ilpo Pajunen of the Helsinki police department.

In spite of the precedent-setting case, officials have still sanctioned motorists for driving days after cannabis use in the period since the ruling.

The reason for the lag can be found in Finland’s criminal code, which calls for a driver to be cited for DUI if their blood has "an active substance or metabolite of a drug used" during the time they were driving or shortly afterwards.

In its judgment, the Supreme Court noted the need for legislative changes. Preliminary drafts state that the drunk driving offence should not be applied to cases where a motorist’s ability to drive cannot be said to have deteriorated due to drug use.

Increase drug-related in DUIs

Growing numbers of drivers on Finnish roads are people pulled over for DUIs caused by drug use, with amphetamines the substance most commonly detected in these cases. Last year, police reported 5,107 such cases.

Cannabis metabolites were the second-most-frequently found substances. In 2018, records showed 1,784 hits of THC in lab samples and 3,794 of THC-COOH.

Moreover, the majority of blood samples handed over to the National Bureau of Investigation, NBI, contained several intoxicants. From the perspective of the subjects’ ability to drive, the least significant substance is not necessarily THC, but other possible drugs – or even the more traditional alcohol.

Police also said that drivers are sent for drug testing when they feel there is reason to suspect drugs are involved. For example, when the breathalyser registers no alcohol, but driving ability is clearly impaired.

Pajunen said that he suspects that drivers who have used cannabis days before and are then able to manage a vehicle do not end up being tested for drugs.

"There must be some kind of trigger to suspect the influence of drugs. Behaviour, driving mistakes or something like that," he added.

For much of the 20th century, the UK and much of the developed world have been engaged in an expensive and ineffective war on cannabis – a psychoactive herbal drug that is not known to have ever poisoned or killed anyone. 

Meanwhile, in plain sight, the pharmaceutical industry has hooked much of Britain and North America on powerful painkillers, known as opioids, that can be highly addictive. Worse still, when they are over-consumed or mixed with alcohol or other legal drugs, they can be lethal. Tragically, this kind of pill-popping Russian roulette has left a trail of dead bodies in nearly every community where these drugs have been widely prescribed. And these unlucky victims are mostly ordinary people under the age of 40. Meanwhile, the death toll keeps mounting unabated.

The situation is not as desperate yet in the UK as it is in the US, where over 400,000 people have died during the last couple of decades from opioid overdoses. This is according to the US Center for Disease Control and Prevention (CDC). That’s roughly 130 people a day. And these sad statistics represent every rung of the socio-economic ladder in the US.

In other words, members of the middle classes are just as hard hit as the socially and economically disadvantaged. This makes opioid painkillers the nation’s biggest accidental killer. And there’s no end in sight. Millions continue to suffer from a physical dependence to these drugs, including a large percentage who are addicted. Tens of thousands of these patients will suffer a very untimely demise. Yet a similarly disturbing trend is now emerging in the UK.

The true extent of Britain’s already entrenched opioid crisis was recently laid bare in a review published last month by Public Health England. It revealed that one in four UK adults are now being prescribed either strong painkillers, antidepressants, sleeping pills or anti-anxiety medication – totalling 12 million people.

This includes five million people being prescribed opioids, numbering one in eight adults. In fact, the UK now has the world’s fastest-growing rate of opioid use.  Prescriptions have risen by 22 per cent from a decade ago to 40 million per year. And an estimated 540,00 Britons are already addicted.

The trouble is opioids should not normally be taken for more than a few weeks, according to the NHS guidelines. Yet patients often find themselves becoming dependent on them for years at a time because doctors cannot offer any viable alternatives, especially for chronic pain.

Yet withdrawing from opioids can be a physically and psychologically torturous experience akin to withdrawing from heroin abuse. Even the NHS admits that very nasty side effects normally occur during patients’ protracted detoxification process.  

Unfortunately, the NHS has yet to come up with particularly successful treatments for opioid dependence and addiction. Hence, the shocking statistics in the Public Health England report.

In response to its publication, Matt Hancock, the health secretary, went into damage control mode by declaring his intention to fix this broken system: "I’m incredibly concerned by this new evidence about the impact over-medicalisation is having…I refuse to let this escalate to the level seen in the United States. This review is a wake-up call…"

So if Hancock is looking to the US as a cautionary tale, he must also be cognizant of the powerful role that medical cannabis is now playing across the pond as a safer alternative to dangerous opioids.

As the UK approaches the one-year anniversary of the legalisation of medical cannabis, it’s time for Hancock to acknowledge cannabis's rightful place in Britain’s modern-day pharmacopeia. He can clearly see what it has done to alleviate the opioid crisis in the US. And it’s time for him to throw British medical patients the same lifeline that North Americans are finding to be extraordinarily therapeutic, and even life-saving in many cases.  

Consider this: in American states where cannabis is legal for medical uses, prescriptions for opioids and anti-depressants have fallen on average almost 30 per cent. Additionally, government data in the US now suggests that prescribing medical cannabis can prevent around 31 per cent of the deaths associated with opioid addiction each year.

It bears repeating that medical cannabis is a non-toxic alternative to opioids that is not considered to be physiologically addictive. And no-one has ever died from consuming too much cannabis or from mixing it with other legal or illegal drugs.

With this in mind, what are you waiting for, Hancock? The “wake up call” that you refer to is for your own government. Give medical cannabis a chance to give opioid-dependant patients their lives back before it’s too late to save them.

For those who watch the marijuana stock market, they know that the past few months have not been too kind to investors. All of this could be changing however as new sentiment could begin to go into effect in the near future. With a large amount of research at one’s hand, it becomes much easier to deduce value in the pot stock market. Research seems to be what separates pro-pot stock investors from those who are just starting out.

With so many different pot stocks to watch, it seems as though the industry is just getting started. The amount of value in the pot stock market is high, but the value seems to be hidden at certain times. This again can be found using ample amounts of information which is highly available on most sources. As we continue to traverse the future of the pot stock market, the hopes are high that we can see some more value come into the industry.

A Canadian Pot Stock to Consider

Stillcanna Inc. (STIL Stock Report) (SCNNF Stock Report) is one of the leading Canadian early-stage life sciences companies currently working on CBD extraction in Europe. The company has stated that their intellectual property should allow them to produce higher quantities of CBD and at a lower cost than most other competitors.

Currently, they have stated that they have an initial extraction contract in Europe that allows them to be the exclusive extractor for Dragonfly BioSciences LLC, a U.K. based CBD supplier. The company has also stated that their recent acquisition of Olimax should allow them to move even deeper into the CBD industry in Europe. For this reason among others, they remain a key pot stock to watch moving forward.

The company recently announced that they have signed into a definitive agreement to supply hemp biomass to the company Sequoya Cannabis. Jason Dussault, CEO of Stillcanna stated that “Stillcanna has always been focused on being a large scale manufacturer and supplier to the global CBD industry. Whether the opportunity is isolate, distillate or biomass, we want to be the industry’s bulk supplier.” This initial biomass agreement is in line with the company’s sales strategy. As they continue to move deeper into the European CBD market, they remain an interesting pot stock to watch.

A Play for the Floridian Market

Trulieve Cannabis (TCNNF Stock Report) is one of the largest vertically integrated pot retailers in the state of Florida. The company also works in other states which makes them a multistate operator, one of the key investments in recent times. With its 36th store opened recently in Florida, the company has been working to build its presence in one of the fastest growing markets in the industry.

The company is also already showing profits which is not something many other pot stocks can say. The hopes are that they can continue to expand into the Florida market as well as other states, which should help them to gain a larger grasp on the pot stock market moving forward.